Inactive Instrument
Checkmate Pharmaceuticals, Inc. Stock
Stocks
CMPI
US1628181083
Biotechnology & Medical Research
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 12/12/2018 | |
Robert Landry
DFI | Director of Finance/CFO | 62 | 31/05/2022 |
James Wooldridge
CTO | Chief Tech/Sci/R&D Officer | 60 | 01/10/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Nouhad Husseini
BRD | Director/Board Member | - | 31/05/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 31/05/22 | Issuer sale | Director | 36,778 | 0.1700% | ||
| 31/05/22 | Issuer sale | Chief Financial Officer | 278,480 | 1.2874% | ||
| 31/05/22 | Issuer sale | Chief Executive Officer | 279,437 | 1.2919% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +0.38% | - | - | 231M | |
| -0.62% | -1.87% | +46.31% | +56.99% | 63.77B | |
| +0.35% | +3.20% | +14.92% | +84.55% | 56.37B | |
| +0.53% | +1.96% | +15.37% | +106.81% | 54.62B | |
| -2.81% | -4.31% | +23.50% | +50.90% | 44.06B | |
| -0.33% | -1.93% | +20.15% | +98.45% | 42.11B | |
| +0.55% | +2.31% | +224.97% | +942.56% | 41B | |
| +3.27% | +47.96% | +112.67% | +96.48% | 34.92B | |
| +1.22% | -1.44% | +14.89% | +47.15% | 32.82B | |
| +0.89% | +20.55% | -42.03% | +373.03% | 24.7B | |
| Average | +0.31% | +7.54% | +47.86% | +206.32% | 43.82B | |
| Weighted average by Cap. | +0.18% | +5.44% | +48.50% | +186.13% |
Employees
31
